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Changes in Anthropometry Measurement among 
Human Immunodefi ciency Virus/Acquired Immune 
Defi ciency Syndrome (HIV/AIDS) 
Patients Received Antiretroviral Treatment
ABSTRAK
Latar belakang: Pada tahun 2005 diperkirakan hampir 38, 6  juta orang terinfeksi HIV dan 2, 8 juta meninggal. 
Bukti-bukti menunjukkan adanya hubungan yang sangat penting antara nutrisi dan perbaikan keluaran 
HIV/AIDS. Status nutrisi yang jelek pada HIV/AIDS dapat disebabkan oleh beberapa faktor, yaitu asupan 
dan absorbsi nutrisi yang tidak memadahi, perubahan metabolik, hipermetabolisme atau gabungan dari 
kesemuanya, serta perubahan di saluran cerna serta interaksi antara obat dan nutrisi. Walaupun kehilangan 
berat badan tetap muncul pada era HAART (highly active antiretroviral therapy), tetapi efek samping HAART 
dan lipodistrofi  menjadi masalah.
Tujuan: Tujuan penelitian ini untuk mengetahui apakah pemberian anti-retroviral berpengaruh terhadap 
perubahan nilai antropometri penderita HIV/AIDS. 
Metode: Penelitian ini menggunakan metode one group pre-posttest design (quasi experimental), dengan menilai 
perubahan nilai antropometri pada subyek penderita HIV sebelum dan sesudah pemberian ARV (Anti-
Retroviral). Analisis data dilakukan secara komputerisasi. 
Hasil: Didapatkan 30 sampel penelitian dengan perubahan antropometri pre dan post ARV 6 bulan. Berat 
badan 51.4±9.12 menjadi 53.6±8.68 dengan nilai p 0.001, Index Massa Tubuh (IMT) 19.98±3.47 menjadi 
20.84±3.35 dengan nilai p 0.001 dan lingkar lengan atas 24.13±3.62 menjadi 24.95±3.48 dengan nilai p 0.003. 
Pemberian obat ARV  selama 6 bulan berpengaruh terhadap perubahan status gizi penderita HIV yang 
dinilai dengan ukuran antropometri. Perubahan yang bermakna di dapatkan pada perubahan berat badan, 
IMT dan lingkar lengan atas. Perubahan nilai antropometri kelompok ARV efavirenz dan non efavirenz 
yang bermakna didapatkan pada perubahan Skinfold thickness (ST) dengan nilai p 0.010. 
Kesimpulan: Tidak didapatkan perubahan bermakna pada nilai antropometri penderita HIV stadium awal 
dibandingkan  stadium lanjut setelah pemberian terapi ARV 6 bulan.
 
Kata kunci: HIV, ARV, antropometri, status nutrisi
ABSTRACT
Background: Estimated nearly 38.6 million people infected by HIV and 2.8 million died in 2005. Evidence 
suggests the existence of  a very important relationship between the output and improved nutritional status 
in HIV/AIDS patients. Poor nutritional status in HIV/AIDS can be caused by several factors, namely the 
intake and absorption of  inadequate nutrition, metabolic changes, hyper metabolism, or a combination 
of  these, changes in the gastrointestinal tract as well as interactions between drugs and nutrients. Losing 
weight remains on the HAART (Highly Active Antiretroviral Therapies) era, but the problems are the side 
effects of  HAART and lipodystrophy.
Objective: The purpose of  this study is to determine the provision of  anti- retroviral effect on changes 
in anthropometric values  people with HIV/AIDS. Method: The study is using the one group pre-posttest 
design (quasi-experimental), by assessing changes in anthropometric values  in subjects with HIV before and 
after the administration of  ARVs. Analysis of  the data is computerized by a computer program.
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Result:  Obtained 30 samples of  the study with anthropometric changes pre and post ARVs 6 months. The 
weight was 51.4 ± 9.12 to 53.6 ± 8.68 with a p-value 0.001. Body Mass Index (BMI) was 19.98 ± 3.47 into 
20.84 ± 3.35 with a p-value 0.001 and upper arm circumference 24.13 ± 3.62 into 24.95±3.48 with a p-value 
0.003. The provision of  antiretroviral drugs for 6 months infl uences the change in nutritional status of  
HIV patients are assessed by anthropometric measure. Signifi cant changes in the changes body weight, BMI 
and upper arm circumference. Changes in anthropometric values  ARV Efavirenz group and non-Efavirenz 
meaningful change signifi cant in skinfold thickness obtained at the value of  p 0.010.
Conclusion: There were no signifi cant changes in anthropometric values  compared to patients with early 
stage HIV and advanced stage after 6 months of  antiretroviral therapy. 
Keywords:  HIV,  antiretroviral drugs,  anthropometric,  nutritional status
INTRODUCTION
In 2005 estimated nearly 38.6 million 
people were infected with HIV and 2.8 
million deaths. The number of  people living 
with HIV increased 3-4 times since 1990 to 
2005, and is likely to continue to rise. Young 
people (between 15-24 years) constitute half  
the population of  people living with HIV 
worldwide and about 6000 people were 
infected in each day.1
C o m p l i c a t i o n s  o f  H u m a n 
Immunodeficiency Virus infection (HIV) to 
changes in nutritional status has been known 
since the early stages of  the epidemic. The spread 
of  HIV around the world have described a 
complex relationship between complications and 
nutritional status. At the individual level, many 
factors contributed to the decline in nutritional 
and health status of  HIV patients.1
Poor nutritional status in HIV/AIDS 
can be caused by several factors. The factors 
including intake and inadequate absorption of  
nutrients, metabolic changes, hyper metabolism 
or a combination of  these, and changes in the 
gastrointestinal tract as well as the interaction 
between the drug and nutrition.2
Complete nutritional assessment should 
include the following parameters: anthropometry 
(body measurements, namely height, weight, 
waist-to-hip circumference, triceps skin fold, 
upper arm circumference), biochemical, clinical, 
diet and socio-economy.3
HIV/AIDS have a higher risk of  
malnutrition due to decreased food intake, poor 
absorption, metabolism changes, treatment 
with antiretroviral (ARV), and infectious and 
chronic conditions such as anorexia, diarrhea, 
fever, nausea and vomiting, mushrooms, and 
anemia.4
Nutritional management in patients with 
HIV/AIDS becomes increasingly complex 
since the introduction of  antiretroviral agents 
in the new form of  the combination which 
called Highly Active Antiretroviral Therapy 
(HAART). HAART gives a better survival time, 
but the side effects and complications are more 
frequent. Before the introduction of  HAART, 
weight loss is an issue of  major nutrients in 
patients with HIV and associated with the 
increased of  morbidity and mortality. Although 
weight loss persists in the era of  HAART, 
but HAART and lipodystrophy side effects is 
become a problem. Lipodystrophy syndrome 
is the loss of  peripheral subcutaneous fat 
and visceral adiposity or accompanying 
the emergence of  metabolic abnormalities, 
especially hyperlipidemia and insulin resistance 
in patients with HIV/AIDS who receive 
HAART.5
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MATERIALS AND METHOD 
This research use the design of  one 
group pre-posttest design (quasi-experimental), 
by assessing changes in anthropometric values 
in subjects with HIV before and after the 
administration of  ARVs. The study was 
conducted in the clinic Edelweiss Sardjito 
General Hospital. The study began in May 
2012 until October 2013. 
Target populations are people who 
suffering from HIV/AIDS in Yogyakarta. 
Affordable populations are those who check 
into the clinic Edelweiss Sardjito General 
Hospital. Inclusion criteria were age 18 to 59 
years old, newly diagnosed with HIV/AIDS, 
have not received antiretroviral therapy, and 
received the maximum ARV therapy less than 
3 months, not illiterate and signed informed 
consent. Exclusion criteria: pregnant women, 
under steroid therapy, suffering from diabetes 
mellitus, liver cirrhosis, renal failure and 
malignancy, physical disability, mental disorder, 
and refusing to be measured.
Estimated minimum sample size in this 
study was 24 people thought to be adequate 
for the observed changes in the value of  
anthropometry. Continuous data are presented 
in the form of  mean ± standard deviation (SB) 
and median (with the range of  minimum and 
maximum values), and categorical data are 
presented in the form of  percentage.6
In ordinal measurement scale, paired 
t-test for unpaired use the data to assess 
the mean difference measured between the 
measurements before and after when the 
data is normally distributed, Wilcoxon signed 
ranks test was used if  data were not normally 
distributed.6
Normality of  data was assessed by 
Kolmogorov-Smirnov test .  Statist ical 
evaluation is done by a computer program. 
The difference was statistically signifi cant set 
of  values  (P <0.05). 6
RESULTS AND DISCUSSION
Obtained about 30 patients infected 
by HIV/AIDS at the Polyclinic Edelweiss 
Dr. Sardjito General Hospital who met 
the inclusion criteria. Data collection was 
performed at the beginning of  the study and 
six months later. 
Obtained a mean age of  study subjects 
was 33.57 ± 6.97 years, consist of  19 men 
(63.3%) and 11 women (36.7%).
Opportunistic infections are found in 
most study subjects candidiasis 12 (40%), more 
than two opportunistic infections 7 (23.3%), 
pulmonary Tb 6 (20%), and 1 each (3.3%) 
for PCP, CMV, Toxoplasma, skin disorders, 
HSV.
Table 1 Baseline characteristics of  the 
study subject’s patients with HIV / AIDS
Variable                        
                 N = 30
n (%) Mean ±SD
Age (year) 
Sex
Man 
Female
Opportunistic infections
TBC 
PCP 
CMV 
Toxoplasmosis 
Candidiasis 
Skin disorders
HSV  
More than one
Stage of  disease
Stage I
Stage II
Stage III
Stage IV
19 (63.3%)
 11 (36.7%)
 6 (20%)
 1 (3.3%)
1 (3.3%)
1 (3.3%)
12 (40%)
1 (3.3%)
1 (3.3%)
7 (23.3%)
1 (3.3%)
 21(70%)
6 (20%)
2 (6.7%)
33.57±6.97
TBC: Tuberculosis; PCP: Pneumocystis carinii pneumonia; 
CMV: Cytomegalic Virus; HSV: Herpes Simplex Virus
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In this research, comparative value 
anthropometry between HIV antiretroviral 
therapy given before and after antiretroviral 
therapy was given. There are signifi cant differences 
in changes in body weight of  2.2 kg with a p-value 
of  0.001, change in BMI of  0.86 kg/m2 with p 
values  of  0.001 and upper arm circumference 
change of  0.82 cm with a p value of  0.003.
Previous studies were comparing the 
anthropometric measure between HIV sufferers 
and healthy people. Whereas in this study were 
compared with HIV anthropometric values 
before the treatment and after 6 months of  
antiretroviral therapy was given. This study 
gives different results with previous studies, 
due to differences in study subjects. In a 
previous study compared anthropometric 
values  and people with HIV healthy, with HIV 
results had lower anthropometric values. In this 
study, the anthropometric values  were higher in 
HIV patients after 6 months of  antiretroviral 
therapy is given.
Changes in anthropometric values  in 
this study were due to the patient's clinical 
improvement to the antiretroviral therapy. 
Provision of  antiretroviral therapy will cause 
a variety of  metabolic abnormalities, which 
cause changes in anthropometric values. Many 
theories explain the effect of  antiretroviral 
drugs on HIV and the effects of  ARVs on 
HIV metabolic abnormalities.7
The infl uence of  drugs directly to the 
HIV virus will cause the eradication of  HIV 
from the body of  the patient. Eradication and 
reduction of  virus will contribute to changes 
in body weight and BMI.8
An analyzed to see the changes of  the 
average change in each variable (mean delta and 
delta) is shown in Table 5. With an average yield 
of  2.19 weight changes, the average change in 
BMI of  0.83, the average change in the value of  
upper arm 0.816, the average change in waist 
and hip ratio of  0.012, the average change in 
skinfold Thickness (-0.12 ). 
Table 3 Average changes in 
anthropometric values  pre ARV and post 
ARV 6 months
Variable                                                       mean±SD
Weight changes
Changes in BMI
Changes Upper arm
Waist Hip Ratio Change
Changes in Average skinfold Thickness
2.19±2.46
0.83±0.96
0.82±1.38
0.012±0.050
-0.12±1.65
From Table 3 above, if  depicted in a 
histogram shown in Figure 1.
Changes in skinfold Thickness (ST) 
obtained in this study meaningful when viewed 
on average by comparing changes anthropometry 
ARV Efavirenz group and non-efavirenz. Based 
on the stage and type of  antiretroviral drugs, 
changes in skinfold Thickness (ST) gained 
signifi cantly in the group with advanced HIV 
who received group therapy Efavirenz (stavudin, 
lamivudine, Efavirenz).
Changes in Skinfold Thickness (ST) 
obtained in this study meaningful when 
Table 2 Changes in anthropometric values  pre ARV and post ARV 6 months
                                           mean±SD     
Variable        (n=30)        Pre ARV                   Post ARV      P value
Weight (kg)
BMI (kg/m2)                                                                                 
Upper arm circumference (cm) 
Hip circumference (cm)
Average Skinfold thickness
51.4±9.12                  53.6±8.68
19.98±3.47                20.84±3.35
24.13±3.62                24.95±3.48
0.88±0.059                 0.89±0.053
9.81±4.66                   9.68±4.21
     0.001
     0.001
     0.003
     0.227
     0.690
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viewed on average by comparing changes 
anthropometry ARV Efavirenz group and 
non Efavirenz.
Average change in theory ST is caused as 
a direct result of  antiretroviral therapy or as a 
result of  metabolic abnormalities. There are 
changes in fat-free mass distribution of  muscle 
in these study subjects. This set of  symptoms 
is often called HIV associated lipodystrophy. 
This term actually includes abnormal fat 
accumulation (lipohipertropic) and reduction 
of  local fat tissue (lipotropic), but most 
patients experienced only lipohipertropic, 
others experienced lipotropic and experiencing 
symptoms of  a mixed fraction.9
Average changes in anthropometric 
values  pre and post antiretroviral HIV drugs 
6 months early stage and advanced stage, with 
the early-stage group n = 22, group advanced 
stage with n = 8, not found signifi cant changes 
in anthropometric values  between multiple 
groups of  early-stage HIV and HIV advanced 
stage (table 5).
Limitations of  this study that not examined 
was the patient's viral load, so it cannot be seen 
fi xes the amount of  virus after antiretroviral 
therapy for 6 months. In this study, the evaluation 
was not performed prior to 6 months of  therapy, 
so it is not known when the changes start 
happening anthropometric values.
Figure 1 Histogram Mean delta changes anthropometric values  
before and after 6 months of  antiretroviral therapy
Table 4 Average changes in anthropometric values  pre and post ARV 6 
months in the group Efavirenz and non Efavirenz
Variable Non Efavirnez (n 13)     (mean ranks)
Efavirenz (n 17) 
(mean ranks) p
Weight change 
Changes in BMI
Changes Upper arm
Waist Hip Ratio Change
Changes Average skinfold Thickness
18.42
18.46
18.27
15.73
20.12
13.26
13.24
13.38
15.32
11.97
0.113
0.113
0.133
0.902
0.010
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CONCLUSION
The provision of  antiretroviral drugs for 6 
months infl uences the change in nutritional status 
of  HIV patients are assessed by anthropometric 
measure. Signifi cant changes in get to change 
weight, BMI and upper arm circumference. 
Changes in anthropometric values  ARV 
Efavirenz group and non-Efavirenz signifi cant 
change was found in skinfold thickness. 
There were no significant changes in 
anthropometric values  compared to patients 
with early stage HIV advanced stage after 6 
months of  antiretroviral therapy.
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